This article was originally published here
Med. HIV. December 23, 2021. doi: 10.1111 / hiv.13218. Online ahead of print.
Objectives: We evaluated the incidence of extrahepatic cancer in people co-infected with HIV / HCV and the potential impact of direct-acting antivirals (DAAs) on the risk of extrahepatic cancer in people co-infected with HIV. / HCV.
DESIGN: Our study cohort included adults who started HIV treatment at a CNICS site in the United States between 1995 and 2017, excluding those who had previously had cancer and had not tested for HCV.
METHODS: We used Cox regression to estimate the risk ratios for the incidence of extrahepatic cancer in patients coinfected with HIV / HCV compared to those with HIV monoinfection. The standardized morbidity ratio (SMR) weights were used to create a ‘pseudopopulation’ in which all patients were treated with antiretroviral therapy (ART) and to compare the incidence of extrahepatic cancer in patients with co-. untreated HIV / HCV infection with the incidence that would have been observed. if they had been successfully treated for HCV.
RESULTS: Of 18,422 adults, 1,775 (10%) had HCV RNA and 10,899 (59%) were on ART at baseline. The incidence rates of any extrahepatic cancer in patients with HIV / HCV coinfection and HIV monoinfection were 1027 and 771 per 100,000 person-years, respectively. In SMR-weighted analyzes, the risk of any extrahepatic cancer in patients with initially untreated HCV coinfection was similar to the risk if they had been successfully treated for HCV. Patients with initially untreated HCV co-infection had a higher incidence of kidney, lung and inflammation cancers than if their HCV had been successfully treated, but these associations were not statistically significant. .
CONCLUSIONS: We did not find evidence that treating HCV co-infection with DAAs would reduce the incidence of extrahepatic cancers in people living with HIV receiving ART.
PMID: 34951105 | DOI: 10.1111 / hiv.13218